Collaboration and Financing Agreements - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended		6 Months Ended			6 Months Ended	0 Months Ended	3 Months Ended			6 Months Ended				3 Months Ended		6 Months Ended			0 Months Ended	3 Months Ended	0 Months Ended	3 Months Ended	0 Months Ended	3 Months Ended	0 Months Ended		3 Months Ended		6 Months Ended		0 Months Ended	3 Months Ended	6 Months Ended	3 Months Ended		6 Months Ended
	May 16, 2014	Jul. 18, 2011	Jul. 18, 2011	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014 Embedded Derivative Liabilities [Member]	Jul. 18, 2011 Healthcare Royalty Financing Agreement [Member]	Jun. 30, 2014 Healthcare Royalty Financing Agreement [Member]	Jun. 30, 2014 Healthcare Royalty Financing Agreement [Member] Embedded Derivative Liabilities [Member]	Jun. 30, 2013 Healthcare Royalty Financing Agreement [Member] Embedded Derivative Liabilities [Member]	Jun. 30, 2014 Healthcare Royalty Financing Agreement [Member] Embedded Derivative Liabilities [Member]	Jun. 30, 2013 Healthcare Royalty Financing Agreement [Member] Embedded Derivative Liabilities [Member]	Dec. 31, 2013 Healthcare Royalty Financing Agreement [Member] Embedded Derivative Liabilities [Member]	Jul. 18, 2011 Healthcare Royalty Financing Agreement [Member] Embedded Derivative Liabilities [Member]	Jun. 30, 2014 Healthcare Royalty Financing Agreement [Member] Common Stock Warrant Liabilities [Member]	Jun. 30, 2013 Healthcare Royalty Financing Agreement [Member] Common Stock Warrant Liabilities [Member]	Jun. 30, 2014 Healthcare Royalty Financing Agreement [Member] Common Stock Warrant Liabilities [Member]	Jun. 30, 2013 Healthcare Royalty Financing Agreement [Member] Common Stock Warrant Liabilities [Member]	Jul. 18, 2011 Healthcare Royalty Financing Agreement [Member] Common Stock Warrant Liabilities [Member]	Jul. 18, 2011 Healthcare Royalty Financing Agreement [Member] Scenario 1 [Member]	Jun. 30, 2014 Healthcare Royalty Financing Agreement [Member] Scenario 1 [Member]	Jul. 18, 2011 Healthcare Royalty Financing Agreement [Member] Scenario 2 [Member]	Jun. 30, 2014 Healthcare Royalty Financing Agreement [Member] Scenario 2 [Member]	Jul. 18, 2011 Healthcare Royalty Financing Agreement [Member] Scenario 3 [Member]	Jun. 30, 2014 Healthcare Royalty Financing Agreement [Member] Scenario 3 [Member]	Jul. 18, 2011 Minimum [Member] Healthcare Royalty Financing Agreement [Member] Scenario 1 [Member]	Jul. 18, 2011 Maximum [Member] Healthcare Royalty Financing Agreement [Member] Scenario 1 [Member]	Jun. 30, 2014 Mallinckrodt LLC Co-Promotion Agreement [Member]	Jun. 30, 2013 Mallinckrodt LLC Co-Promotion Agreement [Member]	Jun. 30, 2014 Mallinckrodt LLC Co-Promotion Agreement [Member]	Jun. 30, 2013 Mallinckrodt LLC Co-Promotion Agreement [Member]	Jun. 27, 2013 Valeant Pharmaceuticals North America LLC Co-Promotion Agreement [Member]	Jun. 30, 2014 Valeant Pharmaceuticals North America LLC Co-Promotion Agreement [Member]	Jun. 30, 2014 Valeant Pharmaceuticals North America LLC Co-Promotion Agreement [Member]	Jun. 30, 2014 Astellas Pharma Us Inc Co Promotion Agreement [Member]	Jun. 30, 2013 Astellas Pharma Us Inc Co Promotion Agreement [Member]	Jun. 30, 2014 Astellas Pharma Us Inc Co Promotion Agreement [Member]	Jun. 30, 2013 Astellas Pharma Us Inc Co Promotion Agreement [Member]	Jul. 31, 2013 Astellas Pharma Us Inc Co Promotion Agreement [Member]
Debt Instrument [Line Items]
Co-promotion agreement termination notice period																																			6 months
Agreement Termination Notice Period Net Sales Contingent																																			30 days
Agreement Termination Notice Period Change of Control Contingent																																			90 days
Sales Revenue, Services, Net																																				$ 1,115,000	$ 1,980,000
Incurred Service Fee Expenses																															0	226,000	100,000	369,000
Tail payment liability related interest expense																																						44,000	146,000	87,000	287,000
Tail payment liability																															491,000		491,000					1,218,000		1,218,000		2,032,000
CoPromotion Agreement Additional Term Increments																																			12 months
Debt instrument, outstanding										30,000,000
Common stock issued and sold to Healthcare Royalty, amount				141,000		141,000		139,000		1,500,000
Common stock issued and sold to Healthcare Royalty, shares				141,045,000		141,045,000		138,927,000		388,601
Common stock issued and sold to Healthcare Royalty, price per share										$ 3.86
Warrant exercisable to Healthcare Royalty, shares		225,000	225,000
Warrant exercisable to Healthcare Royalty, price per share (usd per share)		$ 9.00									$ 9.00
Term of warrant exercisable											10 years
Revenue Interest Rate																							5.00%		2.50%		0.50%		5.00%	5.75%
Net product sales amount received											10,000,000													75,000,000		75,000,000		150,000,000
Fixed Debt Repayment Dates											January 31, 2015, January 31, 2016 and January 31, 2017
Fixed Payments for Jan 31,2015											10,000,000
Fixed Payments for Jan 31,2016											10,000,000
Fixed Payments for Jan 31,2017											10,000,000
Agreement termination date											Mar. 31, 2018
Terminate payment base amount																								52,500,000
Borrowed internal rate of return																								19.00%		17.00%
Repayment of debt						40,041,000	0
Fair value of embedded derivatives												247,000		247,000		233,000
Aggregate net proceed from financing agreement										29,485,000
Financing discounts										476,000							605,000					790,000
Change in fair value									14,000			0	480,000	14,000	562,000			150,000	41,000	272,000	(35,000)
Loss on early extinguishment of debt	$ 1,254,000			$ (1,254,000)	$ 0	$ (1,254,000)	$ 0